- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Setting expectations in patients with prostate cancer receiving HIFU
“[Patients]… need to understand what they’re gaining and what they’re giving up,” says Samuel J. Peretsman, MD, in this video.
In this video, the second installment of Urology Times® Editorial Consultant J. Brantley Thrasher, MD,’s recent interview with Samuel J. Peretsman, MD, regarding high-intensity focused ultrasound, Peretsman explains what he tells patients undergoing HIFU to expect postoperatively. Peretsman is with Urology Specialists of the Carolinas in Charlotte, North Carolina, and Thrasher is executive director of the American Board of Urology.
More videos:
HIFU for prostate cancer: How it works, criteria for treatment, and contraindications
Attorney Kenton H. Steele, Esq, on the medico-legal dangers of friendly prescribing
Dr. Kathleen Kieran discusses peer-reviewed authorship for women in urology
FDA greenlights phase 3 study of LAE201 in mCRPC
May 23rd 2024"Since the phase 2 data of the combination therapy of LAE002 (afuresertib) plus LAE001 demonstrated encouraging anti-tumor activity and safety profile in patients with mCRPC, a following phase 3 pivotal trial design has been discussed with the US FDA and the approval for the protocol has been received this month," said Yong Yue, MD, PhD.
Galen Prostate shows potential to enhance prostate cancer detection
May 20th 2024"We were deeply impressed by Galen's performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely,” says Junya Fukuoka, MD, PhD.
